Authors
Dania Al-Qasrawi, Nayya N Murray, Ryan A Argo, Alicia K Fleming Martinez, Prita Pandya, Anaya Y Clarke, Kayla C Winter, Murli Krishna, Peter Storz, Nicole R Murray, Verline Justilien
Published in
Oncogene. Jun 19, 2026. Epub Jun 19, 2026.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers because it is typically detected at an advanced stage, progresses rapidly, and resists current therapies. Consequently, early diagnostic biomarkers and novel therapeutic targets are urgently needed. Epithelial Cell Transforming Sequence 2 (ECT2) is a Rho family guanine nucleotide exchange factor that was originally identified as an oncoprotein and later shown to regulate cytokinesis. Here, we evaluated ECT2 expression in human PDAC and its functional requirement for transformed growth and tumorigenicity. We found that ECT2 expression is elevated early in PDAC tumorigenesis, remains high throughout progression, and correlates with poor patient survival. Furthermore, a significant pool of ECT2 is mis-localized in the cytoplasm of PDAC cells. Knockdown of ECT2 inhibited 3D-transformed growth, invasion, and in vivo tumor formation while having little impact on PDAC cell cytokinesis. Mechanistically, we found that ECT2 is required for activation of Rac1 and RhoA and downstream MEK/ERK and ROCK signaling, respectively. Consistent with these findings, analyses of PDAC patient datasets revealed a strong association between ECT2 expression and Rho GTPase as well as MEK/ERK and ROCK pathway signatures. Finally, genetic or pharmacologic targeting of ECT2 signaling enhanced PDAC cell sensitivity to MEK inhibition. Taken together, our data identify ECT2 as an early driver of PDAC transformation and highlight it as a promising therapeutic target.
PMID:
42321532
Bibliographic data and abstract were imported from PubMed on 20 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1
- Comments 0